Skip to main content

Table 1 General characteristics of the studies included

From: Impact of vitamin D supplementation on C-reactive protein; a systematic review and meta-analysis of randomized controlled trials

Author, year of publication

Country

Study design

Status

Sample size

Sex (% of women)

Mean age

Intervention

Supplemented the dose of vitamin D (IU/day)

Follow-up duration

A Sadiya (47), 2015

UAE

randomized double-blind clinical trial

vitamin D-deficient obese, type 2 diabetic

87

Male and Female (70%)

49 ± 8

cholecalciferol

(vitamin D3)

phase 1; 6000

phase 2; 3000

6 month

A. Breslavsky (48), 2013

Israel

randomized, placebo-controlled

type 2 diabetes mellitus

47

Male and Female (53.1%)

66.8 ± 9.2

cholecalciferol

(vitamin D3)

1000

12 month

Claudia Gagnon [34], 2014

Australia

randomized, placebo-controlled trial

vitamin D-deficient and at risk of type 2 diabetes

95

Male and Female (71%)

54 years

cholecalciferol

(vitamin D3)

2000–6000

6 month

Edgar Turner Overton [33], 2015

USA

randomized, double-blind, placebo-controlled

HIV-infected

167

Male and Female (9%)

36 years

cholecalciferol

(vitamin D3)

4000

48-week

Gavin Dreyer [30], 2014

UK

randomised controlled trial

non-diabetic chronic kidney disease stage 3–4 and concomitant vitamin D deficiency

38

Male and Female (39.1%)

45.8 (10.0)

ergocalciferol

50,000

6 month

Indrani Sinha-Hikim [25], 2015

USA

randomized

pre-diabetes and hypovitaminosis D

80

Male and Female (70%)

52.0 years

cholecalciferol

(vitamin D3)

85,300 IU ± 16,000

12 month

Isa Gabriela de Medeiros Cavalcante [29], 2015

Brazil

double blind, randomized, placebo-controlled trial

With vitamin D insufficiency

40

Female (100%)

68 ± 6

cholecalciferol

(vitamin D3)

200,000

4 week

Julia Ã…ivo (49), 2015

Finland

double-blind, randomized, parallel

 

59

Male and Female (62.7%)

38 (22–53)

cholecalciferol

(vitamin D3)

20,000

12 month

L. Wamberg (50), 2013

Denmark

double-blind design

 

52

Male and Female (71%)

18 to 50 years

cholecalciferol

(vitamin D3)

7000

 

M.D. Witham (51), 2015

UK

Parallel-group, double-blind, randomised placebo-controlled trial

with chronic fatigue syndrome

50

Male and Female (52%)

49 ± 13

cholecalciferol

(vitamin D3)

100,000

6 month

M.P. BJORKMAN [28], 2009

Finland

randomised double-blind placebo controlled trial

chronically impaired mobility

218

Male and Female

84.5 ± 7.5

cholecalciferol

(vitamin D3)

0

400

1200

6 month

Nafiseh Toghianifar (52), 2015

Iran

double blind randomized clinical trial

with a diagnosis of relapsing remitting multiple sclerosis (RRMS)

94

Male and Female (84.2%)

31.50 ± 7.60

cholecalciferol

(vitamin D3)

50,000

12 week

Nasrin Sharifi (53), 2014

Iran

parallel, double-blind, placebo-controlled

non-alcoholic fatty liver disease (NAFLD)

53

Male and Female (51%)

40.33 ± 8.65

cholecalciferol

(vitamin D3)

50,000

4 month

Ohk-Hyun Ryu [32], 2014

Korea

prospective, randomized, double-blinded, placebo-controlled trial

type 2 diabetic patients

62

Male and Female

54.5 ± 7.4

cholecalciferol

(vitamin D3)

2000

24 week

Pamela R. von Hurst (54), 2010

New Zealand

randomised, placebo-controlled trial

 

81

Female (100%)

45.5

cholecalciferol

(vitamin D3)

4000

6 month

Paulette D. Chandler (55), 2014

USA

Randomized, Placebo-Controlled Trial

 

328

Male and Female (67.7%)

51

cholecalciferol

(vitamin D3)

1000

2000

4000

3 month

Rahaimi (56), 2013

Iran

randomised, placebo-controlled, double-blinded trial

With vitamin D deficiency

50

Female (100%)

30

cholecalciferol

(vitamin D3)

50,000

2 month

Rolf Jorde (57), 2010

Norway

Randomized

overweight and obese

437

Male and Female (64.3%)

47

cholecalciferol

(vitamin D3)

40,000

12 month

Seth I Sokol [31], 2012

USA

double-blind placebo wait-list control design

with CAD and vitamin D deficiency

90

Male and Female (26.5%)

55 ± 9.6

ergocalciferol

50,000

12 week

Tina K. Thethi, 2015

USA

double blind, randomized, placebo-controlled trial

with type 2 diabetes and chronic kidney disease

55

Male and Female (32.7%)

63

Paricalcitol

1 mcg

3 month

Tyler Barker (58), 2015

USA

randomized, double blind, placebo-controlled

 

56

Male and Female (32.7%)

32(7)

cholecalciferol

(vitamin D3)

4000

8000

5 week

Ulla Kampmann (59), 2014

Denmark

double-blind, randomized, placebo-controlled trial

with type 2 diabetes and hypovitaminosis D

15

Male and Female (46.6%)

59.3 ± 4.4

cholecalciferol

(vitamin D3)

5600

11,200

12 week

Zatollah Asemi (60), 2013

Iran

randomized, double-blind, placebo-controlled clinical

healthy pregnant women

48

Female (100%)

29

cholecalciferol

(vitamin D3)

400

25 week